What the Evidence Shows and What It Does Not MedicalDaily Evidence Check Study type: Phase 2b randomized clinical trial Participants: 272 adults with type 2 diabetes, average age 50.8, from 37 sites in China Published in: Annals of Internal Medicine , June 30, 2026 (DOI: 10.7326/ANNALS-25-04623) What it found: Biweekly bofanglutide produced HbA1c reductions and weight loss comparable to weekly semaglutide in Chinese patients with type 2 diabetes What it did not prove: The trial was not conducted in U.S
It strengthens the skin barrier and makes it healthier
Many patients find that keeping a food journal and noting mood patterns helps their healthcare provider adjust medications more precisely
In some countries and regions, it may be used as a prescription drug or research drug in specific medical or research institutions
We keep expectations realistic and put your safety first, which is why the medication is always paired with medical oversight
Furthermore, no serious health risks have been associated with taking this medication long-term, and most people tend to tolerate the drug very well